<DOC>
	<DOC>NCT01202695</DOC>
	<brief_summary>Primary: â€¢ To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: - To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 - To evaluate the immunogenicity of AVP-21D9</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)</brief_title>
	<detailed_description>This is a sequential, dose-escalating healthy volunteer study of the safety and pharmacokinetics of intravenously-infused AVP-21D9.</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Healthy volunteers, between 18 and 45 years of age Normal laboratory (blood test) results Key Prior immunization with anthrax vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>